Figure 1.

Image displaying signaling pathways triggered by binding of growth factors to tyrosine kinase receptor that triggers RAS, RAF, MAPK and ERK pathways leading to cell growth and proliferation. Mutations in BRAF (V600E) which can lead to accelerated cell growth and cancer formation of melanoma cells. Inhibition of mutant BRAF by Vemurafenib (red cross) in the melanoma cells shuts down the signaling pathway causing tumor regression following cell apoptosis, tumor antigen expression and decreased release of cytokines and VEGF. MAPK, mitogen-activated protein kinase; ERK, extracellular-signal regulated kinase; EGF, vascular endothelial growth factor.